Wednesday, September 3, 2014

Precision, Med BioGene get okay for GeneFx Lung

Precision, Med BioGene get okay for GeneFx Lung

March 24, 2014 by · Leave a Comment 

Tweet Med BioGene (TSX-V:MBI) and its commercial partner, Precision Therapeutics, have received regulatory approval of GeneFx Lung under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). As a result, Precision may undertake testing of GeneFx Lung in its CLIA-certified clinical laboratory in Pittsburgh. In a statement, Erinn Broshko, executive chairman of MBI, said regulatory approval […]

Med BioGene partner updates launch of GeneFx Lung

Med BioGene partner updates launch of GeneFx Lung

June 4, 2013 by · Leave a Comment 

Tweet Med BioGene (TSX-V:MBI)  announced that its commercial partner, Precision Therapeutics, presented clinical data and a commercialization update on GeneFx Lung at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago last weekend. Precision said successful completion of the clinical studies to validate the use of Med BioGene’s GeneFx Lung with tissue preserved […]

Med BioGene partner renames lung cancer test

Med BioGene partner renames lung cancer test

March 28, 2013 by · Leave a Comment 

Tweet Med BioGene’s (TSX-V:MBI) commercial partner, Precision Therapeutics, plans to market the Med BioGene LungExpress Dx test under the brand name GeneFx Lung. Precision currently markets a number of tests through its CLIA-certified laboratory, including ChemoFx, BioSpeciFx, miRviewmets2 and GeneFx Colon. Both GeneFx Colon and GeneFx Lung are gene expression-based tests and, accordingly, share the […]

Email Newsletters with Constant Contact
Google+